Navigation Links
Comparative Study Confirms Enox Biopharma's Antimicrobial Superiority to Commercially Available Silver Coated Catheters
Date:8/9/2011

VANCOUVER, British Columbia, Aug. 9, 2011 /PRNewswire/ -- Enox Biopharma, Inc., a leader in nitric oxide delivery technology for the prevention of hospital acquired infections today announced on line publication of scientific results demonstrating superior efficacy in blocking growth of E.coli on the surface of nitric oxide releasing devices as compared to current market leader's silver coated catheters. The paper was published by Professor Yossef Av-Gay's lab at the University of British Columbia.

Enox's nitric oxide device technology renders medical devices like catheters and endotracheal tubes antimicrobial by sequestering nitric oxide within them in a stable state. Nitric Oxide, which is released by the device over a period of about 2 weeks once used clinically, is a potent antimicrobial agent without the drug resistance issues that plague antibiotics. Previous peer reviewed publications have demonstrated the antimicrobial properties of catheters treated with our technology in comparison to untreated catheters.

The paper titled "Comparative efficacy of commercially available and emerging antimicrobial urinary catheters against E. coli infection in vitro" was published in the August 2011 issue of the peer reviewed journal UROLOGY. The paper reports results from an investigation of the ability of four different types of catheters to prevent growth of microorganisms suspended in fluid medium (planktonic growth) and on the surface of catheters in the form of a biofilm. The study compared a non-antimicrobial catheter, an Enox nitric oxide releasing catheter, a silver coated catheter and an antibiotic coated catheter. The study concluded that both the Enox and antibiotic catheters were effective in preventing planktonic growth and biofilm formation whereas the silver and uncoated catheters were not.

"This study confirms the superiority of nitric oxide as an antimicrobial," commented Professor Av-Gay, who is the President and Founder of Enox Biopharma. "Silver proved to be as ineffective as a non-antimicrobial catheter whereas both the Enox and antibiotic catheters were very effective in reducing and eliminating microorganisms. It must be realized that Enox's ability to do this without antibiotics is a significant advantage as use of nitric oxide avoids the antibiotic resistance issues that come with the use of antibiotics."

John Rewcastle, Ph.D., Chief Executive Officer of Enox, commented, "Recently published clinical results completely independent of Enox have shown silver to not perform as well as hoped in a clinical setting. The results from the current study substantiate these observations and provide a scientific foundation for this disappointment. Enox is uniquely positioned to truly render medical devices antimicrobial without the use of antibiotics to reduce hospital acquired infections which represent a major health risk worldwide and a significant financial burden to healthcare systems."

About Enox Biopharma Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into medical devices to make them antimicrobial. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. Enox's device technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes and central venous catheters. Infections from these devices, which are often not reimbursed by Medicare, represent a massive financial burden to healthcare systems worldwide.

For more information, please contact:

John C. Rewcastle, Ph.D, CEO or
Itamar David, CFO
Enox Biopharma, Inc.
604.637.9744 phone

888.224.7259 fax
info@enoxbiopharma.com
www.enoxbiopharma.com


'/>"/>
SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Generic and innovative drug market in CE countries 2011 - Comparative analysis, reimbursement policies and development forecasts for 2011-2013
2. Federal Government Selects Thomson Reuters to Build Tool That Streamlines Comparative Effectiveness Research
3. Special Issue of PharmacoEconomics to Focus on Comparative Effectiveness Research
4. Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients
5. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
6. New National Pharmaceutical Council Report Provides Guidance on Evaluating Comparative Effectiveness Studies
7. Tamaulipas Comparative Wound Healing Test Treatment Successfully Concluded
8. Prospective Clinical Advantages of Trabecular Metal(TM) Technology Highlighted in Comparative Study
9. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
10. Comparative Study Shows Significant Bone In-growth and Advanced Clinical Outcomes Using Zimmers Trabecular Metal(TM) Technology
11. MAP Pharmaceuticals Reports Positive Results From Comparative Pharmacokinetic Trial for its Pediatric Asthma Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)...  Marking its one year anniversary since launching ... risk test, Color Genomics announced a ... impact the most common hereditary cancers affecting both ... analyzes hereditary cancer risks for breast, colorectal, melanoma, ... Color Test is physician ordered and includes genetic ...
(Date:4/28/2016)... 28, 2016 Dr. Vivek Ahuja ... and Ste phen Schmidt ... leading provider of cloud-based software solutions for life sciences, today announced ... bring a wealth of insight to a growing business.  This will ... George Phillips joined ArisGlobal in the position of ...
Breaking Medicine Technology:
(Date:4/29/2016)... York, NY (PRWEB) , ... April 29, 2016 , ... New York City based oral ... . This surgery is a very effective way to treat obstructive sleep apnea. Dr. Jamali ... , Orthognathic surgery is a procedure that involves one or both jaw bones. This surgery ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the market ... funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... and accelerate its technology and product roadmap. , “Jvion is experiencing ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... print media enterprise focused entirely on patients with cancer, today announced that Lynne ... chosen as the 2016 CURE® Extraordinary Healer® for Oncology Nursing , which ...
(Date:4/29/2016)... ... April 29, 2016 , ... Natren, ... animal line of probiotics, Petbiotics ™, as they fondly call them. As ... rescue groups networking for their non-profit organizations. Animal rescues across the nation face ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... awareness for Duchenne muscular dystrophy, and funding for Duchenne research, participated in the ... of the Sarepta Therapeutic’s novel Duchenne drug eteplirsen. The meeting at the Marriott ...
Breaking Medicine News(10 mins):